NCT07204080View on ClinicalTrials.gov

(TNX-1500) in Kidney Transplant Recipients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

March 1, 2028

Study Completion Date

December 31, 2028

Conditions
Kidney TransplantKidney Transplant Failure and RejectionImmunosuppressionImmunosuppression After Kidney Transplantation
Interventions
DRUG

TNX-1500

This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients.

PROCEDURE

Kidney Transplant

Kidney Transplant

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Tonix Pharmaceuticals, Inc.

INDUSTRY

lead

Ayman Al Jurdi, MD

OTHER